title: Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?
authors.affiliation: Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, Paris, France. laurent.beaugerie@sat.aphp.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Beaugerie
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D003092:Colitis / Q000150:complications; D015179:Colorectal Neoplasms / Q000209:etiology / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D009369:Neoplasms / Q000139:chemically induced / Q000209:etiology* / Q000401:mortality; D057285:Precision Medicine / Q000639:trends; D018570:Risk Assessment / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D001241:Aspirin